An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects

Trial Profile

An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs VLA 84 (Primary) ; Alum
  • Indications Clostridium infections
  • Focus Adverse reactions
  • Sponsors Valneva
  • Most Recent Events

    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 11 Apr 2016 Results published in the Vaccine
    • 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top